Skip to main content
Back
INBX logo

Inhibrx Biosciences, Inc.

Data quality: 100%
INBX
NASDAQ Healthcare Biotechnology
$66.46
▲ $3.34 (5.29%)
Mkt Cap: 970.78M
Day Range
$63.56 $68.91
52-Week Range
$10.81 $94.57
Volume
187,777
50D / 200D Avg
$75.51 / $51.38
Prev Close
$63.12

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (631 peers)

Metric Stock Sector Median
P/E -6.9 0.2
P/B 121.5 3.0
ROE % -197.9 3.6
Net Margin % -10773.5 3.8
Rev Growth 5Y % -34.6 9.9
D/E 13.4 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1.75
$1.75 – $1.75
 187.23M 1
FY2029 $0.22
$0.22 – $0.22
 129.25M 1
FY2028 -$0.95
-$0.95 – -$0.95
 97.64M 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-19 -$2.08 -$2.11 -1.4%
2025-11-14 -$2.08 -$2.28 -9.6%
2025-08-13 -$2.92 -$1.85 +36.6%
2025-05-14 -$2.55 -$2.80 -9.8%
2025-03-17 -$2.88 -$3.09 -7.3%
2024-11-14 -$3.06 -$2.84 +7.2%
2024-08-13 -$3.60 $125.48 +3585.6%
2024-06-03 -$1.04 -$1.44 -38.5%

Dividend History

1 yr streak

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

Ex-Date Payment Date Amount Yield
May 30, 2024 Jun 20, 2024 $0.85 5.23%

Key Takeaways

Revenue declined -34.64% annually over 5 years
Earnings declined -108.30% over the past year
Debt/Equity of 13.39 — high leverage
Negative free cash flow of -129.83M
PEG of 0.08 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 584.64%

Growth

Revenue Growth (5Y)
-34.64%
Revenue (1Y)550.00%
Earnings (1Y)-108.30%
FCF Growth (3Y)N/A

Quality

Return on Equity
-197.85%
ROIC-88.06%
Net Margin-10773.46%
Op. Margin-10386.54%

Safety

Debt / Equity
13.39
Current Ratio3.93
Interest Coverage-11.07

Valuation

P/E Ratio
-6.93
Forward P/EN/A
P/B Ratio121.45
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 550.00% Revenue Growth (3Y) -15.02%
Earnings Growth (1Y) -108.30% Earnings Growth (3Y) N/A
Revenue Growth (5Y) -34.64% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.30M Net Income (TTM) -140.06M
ROE -197.85% ROA -95.62%
Gross Margin -91.00% Operating Margin -10386.54%
Net Margin -10773.46% Free Cash Flow (TTM) -129.83M
ROIC -88.06% FCF Growth (3Y) N/A
Safety
Debt / Equity 13.39 Current Ratio 3.93
Interest Coverage -11.07
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years 1 yrs
Valuation
P/E Ratio -6.93 Forward P/E N/A
P/B Ratio 121.45 P/S Ratio 746.76
PEG Ratio 0.08 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 225.76 Fwd Earnings Yield N/A
FCF Yield -13.37%
Market Cap 970.78M Enterprise Value 953.58M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.30M 200,000.0 1.80M 2.19M 7.13M
Net Income -140.06M 1.69B -241.36M -145.23M -81.77M
EPS (Diluted) -9.04 116.58 -5.12 -3.62 -2.15
Gross Profit -1.18M -2.09M 609,000.0 -107.99M 4.44M
Operating Income -135.03M -331.45M -219.22M -129.12M -76.56M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 146.48M 180.77M 307.89M 290.88M 150.45M
Total Liabilities 138.49M 47.18M 264.39M 232.82M 98.07M
Shareholders' Equity 7.99M 133.58M 43.50M 58.06M 52.38M
Total Debt 107.01M 8.05M 210.14M 207.10M 72.14M
Cash & Equivalents 124.22M 152.60M 277.92M 273.87M 131.30M
Current Assets 132.83M 160.40M 295.36M 280.49M 139.11M
Current Liabilities 33.80M 40.73M 56.31M 27.58M 22.45M